Immunosuppressant Small molecules Tuberculosis Crohn’s disease Colon cancer Inclusion Maintenance therapy MALT MARKER Dysbiose Gènes Contraindication Eradication Resistance Microbiote Helicobacter pylori Algorithm Ustekinumab Disease Progression PCR Stricture Ulcerative colitis Clinical guidelines Original Article Clinical Disease progression DNA METHYLATION COLON-CANCER Drug RISK IL12 Disability Surgery Bactéries Methylation HIV Alkylating agents Gene expression Neoadjuvant chemotherapy Upper gastrointestinal tract Méthylation Tailored therapy IBD Cost effectiveness Clinical trial Over 80s Résistance Patients experience Biologics IL23 Endoscopic treatment Consensus Venous thromboembolism Colon Survival T1118 translocation Effectiveness Rituximab Intestinal crypts Inhibitor Inflammatory bowel disease Cancer Primary sclerosing cholangitis Inflammatory bowel diseases Patient-reported outcome Vedolizumab Parvimonas micra Heart disease risk factors Epigenetics Acceptability Colorectal cancer Colibactin and lipids Microbiota MORTALITY Colorectal cancer Inflammatory Bowel Diseases Safety Gene methylation Colectomy CARCINOGENESIS Thérapie ciblée Crohn's disease Eligibility Dysbiosis Cell adhesion Bacteria Monitoring DNA methylation MICROBIOTA Rituximab plus chlorambucil Kidney diseases Colonic epithelial primary cells Anti-TNF agents Epigénétiques Screening Fecal microbiota Immune cells Anti-TNF Genes 18 FDG-PET/CT Therapeutics Biomarker